NXGL
NEXGEL, Inc.NASDAQHealthcare$0.59-5.38%ClosedMarket Cap: $6.3M
As of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
1.15
P/S
0.61
EV/EBITDA
-2.86
DCF Value
$-306.54
FCF Yield
-18.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
39.5%
Operating Margin
-29.3%
Net Margin
-26.3%
ROE
-61.5%
ROA
-28.7%
ROIC
-42.5%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $2.8M | $-970.0K | $-0.12 |
| FY 2025 | $11.4M | $-3.0M | $-0.38 |
| Q3 2025 | $2.9M | $-653.0K | $-0.08 |
| Q2 2025 | $2.9M | $-665.0K | $-0.09 |
Analyst Ratings
View AllMaxim GroupBuy
2026-03-12Trading Activity
Insider Trades
View AllLevy Adam R.director, officer: Chief Executive Officer
SellMon Dec 29
Levy Adam R.director, officer: Chief Executive Officer
SellMon Dec 29
Levy Adam R.director, officer: Chief Executive Officer
SellFri Nov 07
Henry Scott Robertdirector
SellMon Oct 06
Henry Scott Robertdirector
SellMon Oct 06
Company Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
0.62
NEXGEL, Inc. manufactures high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels. Its products are used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company was formerly known as AquaMed Technologies, Inc. and changed its name to NEXGEL, Inc. in November 2019. NEXGEL, Inc. was founded in 1997 and is based in Langhorne, Pennsylvania.